AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...
The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.
(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback